Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 4/20 | 0.58 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 11/20 | 0.48 |
| ▸ | BTK | Q06187 | 9/20 | 0.48 |
| ▸ | JAK1 | P23458 | 2/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27930634 | 0.81 | PAK4 (0.64) | PAK4IRAK4JAK3BTKTTK | |
| SCHEMBL19027156 | 0.80 | PTK2 (0.42) | PAK4IRAK4JAK3JAK1PTK2 | |
| SCHEMBL18984923 | 0.80 | BTK (0.70) | PAK4IRAK4JAK3BTKPTK2 | |
| SCHEMBL14547696 | 0.80 | PAK4 (0.56) | PAK4IRAK4JAK3BTKTTK | |
| SCHEMBL12085405 | 0.79 | ULK1 (0.56) | PAK4IRAK4JAK3BTK | |
| SCHEMBL12085346 | 0.79 | SYK (0.60) | PAK4IRAK4JAK3BTK | |
| SCHEMBL12085351 | 0.79 | PAK4 (0.58) | PAK4IRAK4JAK3BTKTTK | |
| SCHEMBL19020275 | 0.79 | PAK4 (0.48) | PAK4IRAK4JAK3PTK2 | |
| SCHEMBL19020699 | 0.79 | PAK4 (0.48) | PAK4IRAK4JAK3PTK2 | |
| SCHEMBL19020701 | 0.79 | PAK4 (0.48) | PAK4IRAK4JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294235-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2019-05-21 | — | — | US | disclosed |
| US-10023579-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2018-07-17 | — | — | US | disclosed |
| WO-2017106771-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174694-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294235-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | LRRK2, PRKDC, DAPK2 | PAK4 126/4885IRAK4 164/4885JAK3 397/4885 |
| US-20170174694-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | LRRK2, PRKDC, DAPK2 | PAK4 126/4885IRAK4 164/4885JAK3 397/4885 |
| US-10023579-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | LRRK2, PRKDC, DAPK2 | PAK4 126/4885IRAK4 164/4885JAK3 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.